Sunday 20 June 2021

World’s most expensive drug may not be covered by Dutch insurance

Novartis HQ in Switzerland

A drug to treat a rare muscle disease which affects some 20 children in the Netherlands a year should not be included in the basic insurance package unless the price is halved, government advisory group Zorginstituut Nederland has said in new recommendations.

In addition, pharmaceutical company Novartis should also agree to payment on the basis of the actual results, the institute said.

Zolgensma, known as the most expensive drug in the world, is used to treat spinal muscular dystrophy (SMA) and costs €1.9m per treatment. The institute estimates that if the cost were halved, the drug would add some €11m to the Dutch healthcare budget a year.

Last year a crowdfunding campaign raised enough to send a baby known as Jayme to the US for treatment with the drug, which is based on gene therapy.

Novartis also caused controversy in 2019 when it said it would give away 100 treatments in countries outside the US with the recipients to be chosen at random via lottery.

The Netherlands, Belgium and Ireland are conducting joint price talks for the drug with Novartis.

Thank you for donating to

The team would like to thank all the generous readers who have made a donation in recent weeks. Your financial support has helped us to expand our coverage of the coronavirus crisis into the evenings and weekends and make sure you are kept up to date with the latest developments. has been free for 14 years, but without the financial backing of our readers, we would not be able to provide you with fair and accurate news and features about all things Dutch. Your contributions make this possible.

If you have not yet made a donation, but would like to, you can do so via Ideal, credit card or Paypal.